17α-hydroxylase/C17,20-lyase inhibitors

A compound of Formula (I)

• wherein:
• ring A is a 5- to 6-membered heteroaryl containing 1 to 3 heteroatoms each independently selected from N, O or S;
• n is 0, 1, 2, or 3;
• R1 is halo, (C1-C4)alkyl, halo-substituted (C1-C4)alkyl, —OH, CN, —NR1aR1b, —O—R1c, or phenyl optionally substituted with 1 to 3 substituents selected from halo, (C1-C4)alkyl, or halo-substituted (C1-C4)alkyl, where R1a is H or (C1-C4)alkyl, R1b is (C1-C4)alkyl, —C(O)—(C1-C4)alkyl, —C(O)—(C3-C6)cycloalkyl, phenyl, or —CH2—(C3-C6)cycloalkyl, and R1c is (C1-C4)alkyl, halo-substituted (C1-C4)alkyl, —CH2—(C3-C6)cycloalkyl, or 5- to 6-membered heteroaryl containing 1 to 3 heteroatoms selected from O, N or S and optionally substituted with 1 to 3 substituents selected from halo, (C1-C4)alkyl, or halo-substituted (C1-C4)alkyl;
• R2, R3, R4, and R5 are each independently H or (C1-C4)alkyl, or R2 or R3 taken together with R4 or R5 forms a double bond or a cyclopropyl;
• R6 is pyridin-3-yl optionally substituted with 1 to 3 substituents each independently selected from halo, —OH, —CN, (C1-C4)alkyl, halo-substituted(C1-C4)alkyl, hydroxy-substituted (C1-C4)alkyl, (C3-C5)cycloalkyl, where said cycloalkyl is optionally substituted with hydroxy, —NH2, —NH(C1-C4)alkyl, —N((C1-C4)alkyl)2, —NHC(O)—(C1-C4)alkyl, —C(O)NH2, —C(O)—NH(C1-C4)alkyl, —C(O)—N((C 1-C4)alkyl)2, —C(O)—O(C1-C4)alkyl, —(CH2)r—O(C1-C4)alkyl, —(CH2)r—CH(O(C1-C4)alkyl)2, —(CH2)r—NH—(C3-C6)cycloalkyl, or pyrrolidinl-yl-(CH2)r—, where r is 0, 1 or 2;
• or a pharmaceutically acceptable salt thereof.